Title:
MACROCYCLIC HETEROCYCLIC COMPOUNDS AS EGFR INHIBITORS, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/135432
Kind Code:
A1
Abstract:
The present invention relates to the field of medicinal chemistry and relates to a class of macrocyclic heterocyclic compounds as EGFR inhibitors, and the use thereof; specifically provided in the present invention are compounds as represented by formula (I) or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal, or a prodrug thereof, a preparation method therefor, a pharmaceutical composition containing said compounds, and the use of said compounds or composition in the treatment of EGFR-mediated diseases.
Inventors:
WANG XIAOWEI (CN)
LIANG CHENG (CN)
FANG QIN (CN)
WANG YAZHOU (CN)
ZHAO LIWEN (CN)
HAN YAOHUI (CN)
CHEN XINGGUANG (CN)
LI XUE (CN)
LUO CHENG (CN)
QUAN XU (CN)
YU SHUJIA (CN)
WANG HAI (CN)
LIANG CHENG (CN)
FANG QIN (CN)
WANG YAZHOU (CN)
ZHAO LIWEN (CN)
HAN YAOHUI (CN)
CHEN XINGGUANG (CN)
LI XUE (CN)
LUO CHENG (CN)
QUAN XU (CN)
YU SHUJIA (CN)
WANG HAI (CN)
Application Number:
PCT/CN2021/140277
Publication Date:
June 30, 2022
Filing Date:
December 22, 2021
Export Citation:
Assignee:
NANJING SANHOME PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K31/4545; C07D498/18; A61K31/496; A61K31/4995; A61K31/529; A61P35/00; A61P35/02; C07D498/22
Domestic Patent References:
| WO2020260252A1 | 2020-12-30 |
Foreign References:
| CN113527335A | 2021-10-22 |
Other References:
ENGELHARDT, HARALD ET AL.: "Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 22, 5 November 2019 (2019-11-05), XP055821569, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01169
Attorney, Agent or Firm:
NANJING ZHONGLIAN PATENT AGENCY CO., LTD. (CN)
Download PDF: